Projects per year
Personal profile
Personal Statement
I obtained a pharmacy degree from the University of Strathclyde in 1979 followed by a PhD in Physiochemical Aspects of Anti-Cancer Drug Targeting Systems in 1984. I worked during pre-registration in industrial and hospital pharmacy settings, joined SIPBS as a lecturer in 1984 and was appointed Director of the Formulation Unit in 1992. The Unit's role is to characterise, analyse, formulate and manufacture putative anti-cancer drugs accepted by CRUK's New Agents Committee for use in human clinical trials, where I have now been pharmaceutically responsible for over 20 novel NCE's. Arising from this are research interests, which include medicinal and analytical chemistry, drug physiochemistry, formulation for both small volume and parenteral and oral products and the GMP production of specialist pharmaceutical products for phase l clinical trials. The latter incorporates research areas such as microbiology and lyophilisation. In addition related research is conducted in drug targeting and delivery systems for cancer chemotherapy for example the utilisation of synthetic Low Density Lipoprotein systems. I have over £10 million in personal career grant income and over 150 published papers, conference abstracts and presentations.
Undergraduate teaching is limited due to the nature of the Formulation Unit's activities to introductory and specialist courses associated with the areas above applicable to undergraduate pharmacists. Since 1987 I have been involved in post qualification education teaching for the pharmaceutical industry and initiated and teach on the joint SIPBS-David Begg Associates Qualified Persons training course which has been running since 1991.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
DHSC The Future Manufacturing Vaccine Hub: Accelerating the manufacture and deployment of cost effective vaccines
Perrie, Y. (Principal Investigator) & Halbert, G. (Co-investigator)
EPSRC (Engineering and Physical Sciences Research Council)
1/09/23 → 28/02/28
Project: Research
-
-
Quality by digital design in action: a workflow for crystallisation and isolation
Houson, I., Siddique, H., Chong, M. W. S., Robertson, M., Turner, A. J., Nordon, A., Osman, A., Galindo, A., Dunn, A. S., Johnston, B., Benyahia, B., Brown, C. J., Mustoe, C. L., Price, C. J., Reilly, C. D., Adjiman, C. S., Jackson, G., Prasad, E., Halbert, G. & Feilden, H. & 17 others, , 25 Dec 2025, In: International Journal of Pharmaceutics. 686, 15 p., 126343.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Quality by digital design to accelerate sustainable medicines development
Mustoe, C. L., Turner, A. J., Urwin, S. J., Houson, I., Feilden, H., Markl, D., Al Qaraghuli, M. M., Chong, M. W. S., Robertson, M., Nordon, A., Johnston, B. F., Brown, C. J., Robertson, J., Adjiman, C., Batchelor, H., Benyahia, B., Bresciani, M., Burcham, C. L., Cardona, J. & Cottini, C. & 29 others, , 20 Aug 2025, In: International Journal of Pharmaceutics. 681, 24 p., 125625.Research output: Contribution to journal › Article › peer-review
Open AccessFile7 Citations (Scopus)23 Downloads (Pure)
Datasets
-
Data for: "Stability properties of the first-in-class anti-cancer IgE antibody drug, MOv18 IgE"
Considine, P. (Creator), Punnabhum, P. (Creator), Davidson, C. (Creator), Kreiner, M. (Creator), Halbert, G. (Creator) & Rattray, Z. (Creator), University of Strathclyde, 23 May 2025
DOI: 10.15129/1f1c7b31-8be2-4434-b786-f21d9bf8f236
Dataset
-
Data for: "An Additive Manufacturing MicroFactory: Overcoming brittle material failure and improving product performance through tablet Micro-structure control for an immediate release dose form"
Prasad, E. (Creator), Robertson, J. (Editor) & Halbert, G. (Supervisor), University of Strathclyde, 2 Sept 2024
DOI: 10.15129/880df3f3-bb94-4e14-9802-cc61ae9689e3
Dataset
Prizes
-
Fellow of Royal Society of Chemistry
Perrie, Y. (Recipient), Halbert, G. (Recipient) & Edrada-Ebel, R. (Recipient), 5 Mar 2024
Prize: Fellowship awarded competitively
-
Fellow of the Royal Pharmaceutical Society (FRPS)
MacKay, S. (Recipient), Boyter, A. (Recipient), Watson, M. (Recipient), Halbert, G. (Recipient), Perrie, Y. (Recipient), Akram, G. (Recipient), Bennie, M. (Recipient), Rattray, Z. (Recipient) & Florence, A. (Recipient), 2024
Prize: Fellowship awarded competitively
Activities
-
Opening up the pharmaceutical formulation space for Additive Manufacturing
Prasad, E. (Speaker), Robertson, J. (Contributor) & Halbert, G. (Contributor)
6 Oct 2021Activity: Talk or Presentation › Oral presentation
-
ToF-SIMS imaging of amorphous solid dispersions: a stability study
Paladino, E. (Speaker), Doerr, F. (Contributor), Onyemelukwe, I. I. (Contributor), Gilmore, I. (Contributor) & Halbert, G. (Contributor)
23 Oct 2019Activity: Talk or Presentation › Oral presentation
Impacts
-
Improved health and survival rates for patients with malignant brain and prostate cancer, and economic benefit from new chemotherapy treatments.
Halbert, G. (Participant)
Impact: Impact - for External Portal › Economic and commerce, Health and welfare - new products, guidelines and services
File
Equipment
-
Agilent 1290 Infinity HPLC 10
Strathclyde Institute Of Pharmacy And Biomedical SciencesFacility/equipment: Equipment
-
Agilent 1290 Infinity HPLC 11
Strathclyde Institute Of Pharmacy And Biomedical SciencesFacility/equipment: Equipment